FOR A MAJOR killer of the very young and the very old, respiratory syncytial virus (RSV) gets scant public attention. Although the virus usually causes mild, coldlike symptoms, it can inflame small airways in the lungs of babies and vulnerable adults, triggering severe pneumonia. Globally, RSV is the second leading cause of pediatric deaths after malaria. Among adults, it’s responsible for up to 10,000 deaths and 160,000 hospitalizations annually in the U.S., mostly among the elderly or immunocompromised.
RSV made headlines this past May, however, when the FDA approved the first vaccine for the disease. The product, known as Arexvy, was OKed for adults over 60. Its manufacturer, biopharma company GSK, beat several rivals to the finish line — including Pfizer, whose RSV vaccine Abrysvo received approval for the same…